The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn More
In my final year as a Technion undergraduate, I tested positive for a BRCA mutation. This means I face an increased risk for breast and other cancers. This revelation altered the course of my life — making my longstanding desire to do scientific research not just an academic pursuit, but a personal one. I earned […]
A discovery by Prof. Ami Aronheim and his team at the Technion–Israel Institute of Technology shows that the growth of cancerous tumors may actually combat cardiac dysfunction and reduce fibrosis, the scarring process that stiffens the heart muscle. “The failing heart can beat much better in the presence of cancer cells or a tumor,” said lead investigator Aronheim, dean of the Technion’s Ruth and Bruce Rappaport Faculty of Medicine, speaking to The Times of Israel. “This is very surprising,” Aronheim said. Currently, no drugs exist that can reverse fibrosis or improve the heart muscle once it has been damaged, he…
IceCure Medical’s tumor-freezing treatment ProSense has nabbed FDA approval, making it the first medical device of its kind to be endorsed for the local treatment of breast cancer. The Israeli medical technology company saw its shares jump more than 17% afterhours Friday, Oct. 3, after the company announced the approval. Shares lost some of their gains by Monday morning and were trading up about 8% from Friday’s close. Treatment with ProSense involves a minimally invasive outpatient procedure that aims to destroy tumors by freezing them, all without the need for surgical removal of breast tissue. This approach also allows for…
Maayan Kinsbursky “I am a 31-year-old industrial designer, a wife, and a mother to a baby. I hold a bachelor’s degree in industrial design from Bezalel Academy of Arts and Design and a master’s degree in industrial design from the Technion – Israel Institute of Technology, which I completed with honors. My thesis focused on […]
At the Technion, researchers are unraveling the fierce battles our cells wage against viruses, uncovering how gut microbes shift the tide in chronic disease, and revealing the brain’s surprising power to heal broken hearts. From revolutionary dual-target antibodies that outsmart the flu to groundbreaking discoveries in inflammation, these breakthroughs are rewriting the future of medicine — promising lifesaving therapies that arrive faster, hit harder, and change everything.
As the leading cause of death in children living in developed countries, pediatric cancer is long overdue for a safer, more targeted treatment approach – and Technion Professor Alejandro Sosnik believes he may have found one. In his lab focusing on pharmaceutical nanomaterial science in the Technion’s Faculty of Materials Science and Engineering, Prof. Sosnik […]
Cancer is the leading cause of death in Israel for both men and women, and one of the leading causes of death in the Western world. In light of this tragic fact, cancer research is considered particularly active, and in recent years it is focused on targeted therapies — treatments that aim to more effectively attack cancer cells while reducing general systemic damage, as occurs with broad-spectrum chemotherapy treatments that harm other body organs. NanoGhost, an Israeli biotech company, introduces one of the most exciting and promising technologies of recent years in this field.[OB1] NanoGhost develops a highly selective first-in-class…
“Lung cancer and liver cancer are in the top three deadliest cancers in the world, simply because we catch it way too late,” said Ilay Marom, the co-founder and Chief Operating Officer at NaNose Medical. Founded around five and a half years ago, NaNose Medical is working to change that reality. Launched “with the purpose of revolutionizing screening tests and early diagnosis,” Marom explained in conversation with CTech, the Israeli startup is pioneering non-invasive diagnostics based on breath biomarkers. It’s technology that holds particular significance for the early detection and future treatment of liver disease and lung cancer. “Everybody knows…
Considered to be one of the greatest revolutions in cancer treatment, immunotherapy enhances the immune system’s ability to target and destroy cancer cells efficiently. One of the key challenges in immunotherapy is the uncertainty regarding patients’ responses—not all patients respond to the treatment, and some may experience side effects without meaningful therapeutic gain. Therefore, there is a need to identify biomarkers that can predict treatment effectiveness based on individual patient data. New and promising findings on this topic are now presented in a study by Technion researchers published in the journal Cell Genomics. The research was led by Prof. Keren…
Novocure (Nasdaq: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields), visits the Nasdaq MarketSite in Times Square. The company is celebrating its 25th anniversary. In honor of the occasion, Ashley Cordova, CEO, rings the Opening Bell. Novocure was founded in 2000 by Technion Professor Emeritus Yoram Palti.
Researchers at the Technion Faculty of Biology have identified potential new innovative genetic therapies for cancer and brain diseases. The findings were supported by the Israel Science Foundation (ISF), the US-Israel Binational Science Foundation (BSF), NSF-BSF Molecular and Cellular Biosciences, and the National Institutes of Health (NIH) and were published in the peer-reviewed journal Nucleic Acids Research. The study was conducted in collaboration with the research group of Professor Heather Hundley from Indiana University and was led by Ph.D student Berta Eliad, master’s student Noa Schneider, and their advisor, Associate Professor Ayelet Lamn.
This 3D-printed postmastectomy bra could be the next best breast prosthesis. Here’s how the technology works. Tal was diagnosed with stage 3 breast cancer in the fall of 2019. She underwent chemotherapy, a mastectomy, and whole breast radiation. Tal wasn’t a candidate for reconstructive surgery, because radiation thinned her skin and reduced its elasticity. Determined to move on and regain confidence, she tried her first breast prosthesis at a hospital. “It was knitted and looked like a pillow,” she says. “It made me laugh because it looked nothing like a real breast.” U·Bra was co-developed by Technion Professor Yoav Sterman.